समाचार
Superluminal to receive payments, equity investment, royalties Lilly, Novo pursuing GPCR-targeting drugs for obesity Superluminal's lead candidate not part of deal with Lilly Aug 14 (Reuters) - Eli ...
Eli Lilly and Co LLY has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other cardiometabolic ...
MSN पर होस्ट किया गया1माह
Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI
(Reuters) -Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic ...
वे परिणाम जो आपके लिए पहुँच योग्य नहीं हो सकते हैं, वे वर्तमान में दिखा रहे हैं.
पहुँच से बाहर के परिणामों को छुपाएँ
प्रतिक्रिया